Low-molecular-weight heparin during percutaneous coronary interventions: Rationale, results, and recommendations

Catheterization and Cardiovascular Interventions

Volumn 60, Issue 2, 2003, Pages 185-193

  Levine, Glenn N ^a,b   Ferguson III, James J ^a,c,d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c ST LUKE S EPISCOPAL HOSPITAL   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Angioplasty; Anticoagulation; Enoxaparin

Indexed keywords

ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULANT THERAPY; BLEEDING; CLINICAL PRACTICE; HEART CATHETERIZATION; HEART MUSCLE ISCHEMIA; HUMAN; REVIEW; ST SEGMENT ELEVATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ACUTE DISEASE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CLINICAL TRIALS; CORONARY DISEASE; ENOXAPARIN; HEALTH PLANNING GUIDELINES; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INTRAOPERATIVE CARE; SYNDROME;

EID: 0141678962     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.10640     Document Type: Review

References (51)

1. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999;100:1593-1601.
2. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease: efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events study group. N Engl J Med 1997;337:447-452.
3. Goodman SG, Fitchett D, Armstrong PW, et al. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 2003;107:238-244.
4. Smith SC, Dove JT, Jacobs AK, et al. ACC/AHA guidelines for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol 2001;37:2215-2238.
5. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605-613.
6. Fragmin and Fast Revascularisation During Instability in Coronary Artery Disease (FRISC II) investigators. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999; 354:701-707.
7. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-1887.
8. Fox KA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Lancet 2002;360:743-751.
9. Fareed J, Jeske W, Hoppensteadt D, et al. Are the available low-molecular-weight heparin preparations the same? Sem Thrombo Hem 1996;22(Suppl 1):77-91.
10. Levine GN, Ali MN, Schafer AI. Antithrombotic therapy in patients with acute coronary syndromes. Arch Intern Med 2001;161: 937-948.
11. Bara L, Bloch MF, Zitoun D, et al. Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor. Thromb Res 1993;69: 443-452.
12. Schafer AI, Ali MN, Levine GN. Hemostasis, thrombosis, fibrinolysis, and cardiovascular disease. In: Braunwald EB, Zipes DP, Libby P, editors. Heart disease, 6th ed. Philadelphia: W.B. Saunders; 2003. p 2099-2132.
13. Bendetowicz AV, Kai H, Knebel R, et al. The effect of subcutaneous injection of unfractionated and low molecular weight heparin on thrombin generation in platelet rich plasma: a study in human volunteers. Thromb Haemost 1994;72:705-712.
14. Zed PJ, Tisdate JE, Borzak S. Low-molecular-weight heparins in the management of acute coronary syndromes. Arch Int Med 1999;159:1849-1857.
15. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-1335.
16. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337:688-698.
17. Antman EM, Handin R. Low-molecular-weight heparins: an intriguing new twist with profound implications. Circulation 1998; 98:287-289.
18. Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low-molecular-weight heparin. Chest 1998;114:489S-510S.
19. Bucklye M, Sorkin EM. Enoxaparin: a review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders. Drugs 1992;44:465-497.
20. Rabah MM Premmereur J, Graham M, et al. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol. 1999;84:1391-1395.
21. Anonymous. Physicians desk reference, 57th ed. Thompson PDR, Montvalle, NJ. 2003. p 739-744.
22. Montalescot G, Polle V, Collet JP, et al. Low molecular weight heparin after mechanical heart valve replacement. Circulation 2000;101:1083-1086.
23. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease: efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events study group. N Engl J Med 1997;337:447-452.
24. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999;100:1593-1601.
25. Thrombolysis in Myocardial Infarction (TIMI) 11A trial investigators. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. J Am Coll Cardiol 1997;29:1474-1482.
26. Becker RC, Spencer FA, Gibson M, et al. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J 2002;143:753-759.
27. Bara L, Billaud E, Gramond G, et al. Comparative pharmacokinetics of a low molecular weight heparin and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res 1985;39:631-636.
28. Andrassy K, Schenfelder V. Are the pharmacokinetic parameters of low molecular weight heparins predictive of their clinical efficacy? Thromb Res 1996;81(Suppl 2):S29-S38.
29. Preisack MB, Boban R, Meisner C, et al. Incidence, outcome and prediction of early clinical events following percutaneous transluminal coronary angioplasty: a comparison between treatment with reviparin and unfractionated heparin/placebo (results of a sub-study of the REDUCE trial). Eur Heart J 1998;19:1232-1238.
30. Karsch KR, Preisack MB, Baildon R, et al. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty: results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). J Am Coll Cardiol 1996;28:1437-1443.
31. Young JJ, Keriakes DJ, Grines CL, et al. Low-molecular-weight heparin therapy in percutaneous coronary intervention: the NICE 1 and NICE 4 trials. J Invas Cardiol 2003;12(Suppl E):E14-E18.
32. Kereiakes DJ, Grines C, Fry E, et al. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invas Cardiol 2001;13:272-278.
33. Kereiakes DJ, Fry E, Matthai W, et al. Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: "NICE guys finish first." J Invas Cardiol 2000;12(Suppl A):1A-5A.
34. Bhatt DL, Lee BI, Casterella PJ, et al. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 2003;41: 20-25.
35. Choussat R, Montalescot G, Collet JP, et al. A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol 2002;40:1943-1950.
36. Kereiakes DJ, Kleiman NS, Fry E, et al. Dalteparin in combination with abciximab during percutaneous coronary intervention. Am Heart J 2001;141:348-352.
37. EPISTENT investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87-92.
38. Topol EJ, Molitemo DJ, Herrmann HC, et.al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularizations. N Engl J Med 2001;344:1888-1894.
39. EPILOG investigators. Platelet glycoprotein IIb/IIIa receptor blockage and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
40. ESPRIT investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized, placebo-controlled trial. Lancet 2001;356:2037-2044.
41. Chew DP, Bhatt DL, Lincoff AM, et al. Defining the optimal activated clotting time during percutaneous coronary intervention. Circulation 2001;103:961-966.
42. Fox KAA, Antman EM, Cohen M, et al. Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention. Am J Cardiol 2002;90:477-482.
43. Ferguson JJ. The use of enoxaparin and IIb/IIIa antagonists in acute coronary syndromes, including PCI: final results of the NICE-3 study. J Am Coll Cardiol 2001;37(Suppl A):365A.
44. Collet JP, Montalescot G, Lison L, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001;103:658-663.
45. Martin JL, Fry ETA, Serano A, et al. Pharmacokinetic study of enoxaparin in patients undergoing coronary intervention after treatment with subcutaneous enoxaparin in acute coronary syndromes: the PEPCI study. Eur Heart J 2001;22(Suppl):14.
46. Sanderink GJ, Guimart CG, Ozoux ML, et al. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 2002;105:225-231.
47. Cadroy Y, Pourrat J, Baladre MF, et al. Delayed elimination of enoxaparine in patients with chronic renal insufficiency. Thromb Res 1991;63:385-390.
48. Sanderink GJ, Liboux AL, Jariwala N, et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther 2002;72:308-318.
49. Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA guidelines for coronary artery bypass graft surgery. J Am Coll Cardiol 1999;34:1262-1346.
50. Kereiakes DJ, Montalescot G, Antman EM, et al. Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus. Am Heart J 2002;144:615-624.
51. Bhatt DL, Lee BI, Casterella PJ, et al. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 2003;41: 20-25.